Handelsavisen
prelaunch
Companies ›Healthcare ›347850.KQ
34
347850.KQ — KOSDAQ Biotechnology & Medical Research

DND PharmaTech Inc

$76 000,00
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,00 %
Op margin
-791,0 %
ROE
-29,6 %
Net margin
-548,1 %
Debt / equity
0,08
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

DND PharmaTech Inc is a biotechnology and medical research company that operates within the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.

Business. DND PharmaTech Inc (347850.KQ) is a biotechnology and medical research company operating within the healthcare sector. The firm is listed on the KOSDAQ exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-29,6 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 347850.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 347850.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    DND PharmaTech Inc (347850.KQ) is a biotechnology and medical research company operating within the healthcare sector. The firm is listed on the KOSDAQ exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    DND PharmaTech Inc maintains a strong liquidity position, with a current ratio of 9.41, indicating that the company has significantly more current assets than current liabilities. The company's cash and equivalents amount to 32,883,741,890 KRW, which is a substantial portion of its total assets of 97,539,472,150 KRW. However, the company's liquidity is not supported by strong operating cash flow, which is negative at -21,138,952,810 KRW.

    The company's profitability is weak, with a return on equity of -0.2963 and a return on assets of -0.2415, both significantly below the industry median for biotechnology firms. Operating income is negative at -33,992,611,600 KRW, and net income is also negative at -23,554,579,040 KRW. These figures suggest that the company is not currently generating sufficient revenue to cover its operating costs and is experiencing significant losses.

    DND PharmaTech Inc's revenue is concentrated in the pharmaceuticals and medical research segments, with no disclosed geographic diversification in the provided data. The company's total revenue for the period is 4,297,604,950 KRW, but the absence of segment-specific revenue data limits the ability to assess the contribution of different business lines to overall performance.

    The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. Analyst estimates suggest a mean revenue of 12,000,000,000 KRW, but the company's reported revenue is significantly lower at 4,297,604,950 KRW. The negative operating and net income figures indicate that the company is not currently on a path to profitability.

    Risk factors for DND PharmaTech Inc include its negative operating cash flow and the absence of positive returns on equity and assets. The company's debt-to-equity ratio is 0.08, which is relatively low, but the negative free cash flow of -18,513,050,990 KRW suggests that the company may face challenges in maintaining its current capital structure without external financing. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected.

    Recent events and filings do not provide specific details on the company's operations or strategic direction. The absence of detailed disclosures in the provided data limits the ability to assess the company's recent performance and future prospects.

    Key takeaways
    • DND PharmaTech Inc has a strong liquidity position but is experiencing significant operating and net losses.
    • The company's return on equity and assets is negative, indicating poor profitability.
    • Revenue is concentrated in the pharmaceuticals and medical research segments, with no geographic diversification disclosed.
    • Analyst estimates suggest a potential for revenue growth, but the company's current financial performance does not support this outlook.
    • The company's low debt-to-equity ratio is a positive, but the negative free cash flow may necessitate external financing.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $76 000,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $79.49B
    Net cashⓘ
    $26.64B
    Current ratioⓘ
    9.4
    Debt / equityⓘ
    0.1
    ROAⓘ
    -24.1%
    ROEⓘ
    -29.6%
    Cash conversionⓘ
    90.0%
    CapEx / revenueⓘ
    -1.5%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Operating income · consensus-26,0B KRW

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-791,0 %Below median
    Net Margin-548,1 %Below median
    ROE-29,6 %Below median
    Capex / Rev-1,5 %Above P75
    D/E0,08Below median
    Cash Conv0,90Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • DND PharmaTech Inc Market data — financials · 2026-05-26
    • DND PharmaTech Inc Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    347850.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage